Department for Gynecology and Obstetrics, Marienhospital Bottrop gGmbH Trials

Department for Gynecology and Obstetrics, Marienhospital Bottrop gGmbH	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Kolberg, Hans-Christian

NeoON, NCT05036005: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label

Recruiting

108

Europe

Ontruzant, SB3, Chemotherapy, Pertuzumab

Institut fuer Frauengesundheit, Samsung Bioepis Co., Ltd.

Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer

04/23

07/23

CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

Recruiting

1000

Europe

Ribociclib

Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals

Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer

10/24

10/26

SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting

1332

Europe

Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy

GBG Forschungs GmbH, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER

HER2-negative Breast Cancer, Triple Negative Breast Cancer

03/27

03/29

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

neoMono, NCT04770272 / 2020-001651-40: Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy with Atezolizumab - CTX Therapy

Completed

416

Europe

Atezolizumab 840 MG in 14 ML Injection, Tecentriq, Atezolizumab 1200 MG in 20 ML Injection, Carboplatin, Paclitaxel, Epirubicin, Cyclophosphamide, Biopsy Arm A, Biopsy Arm B, Surgery

Palleos Healthcare GmbH, Roche Pharma AG, Phaon Scientific GmbH, University Hospital, Essen, University Hospital Erlangen

Triple-negative Breast Cancer

07/23

10/24

ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting

1/2

400

Europe, US, RoW

Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio

Stemline Therapeutics, Inc.

Breast Cancer, Metastatic Breast Cancer

12/26

12/28

NCT04101851: Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients with RCR and PCR in the Breast After NAST

Active, not recruiting

N/A

350

Europe

omission of SLNB

Toralf Reimer, MD PhD, European Breast Cancer Reseach Association of Surgical Trialists, University Medicine Rostock, Rostock, Germany (sponsor), Else Kröner-Fresenius-Stiftung (funding), German Society of Senology (funding)

Breast Cancer Female, Breast Cancer

01/28

AXSANA, NCT04373655: AXillary Surgery After NeoAdjuvant Treatment

Recruiting

N/A

3000

Europe

European Breast Cancer Reseach Association of Surgical Trialists, AWOgyn, AGO-B, North Eastern German Society of Gynaecological Oncology, German Breast Group, Claudia von Schilling Foundation for Breast Cancer Research, Ehmann-Stiftung Savognin

Breast Cancer

04/30

PROOFS, NCT05792150: -Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS

Recruiting

N/A

1470

Europe

West German Study Group, Agendia

Female Breast Cancer

03/35

06/35

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Kolberg, Hans-Christian

NeoON, NCT05036005: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label

Recruiting

108

Europe

Ontruzant, SB3, Chemotherapy, Pertuzumab

Institut fuer Frauengesundheit, Samsung Bioepis Co., Ltd.

Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer

04/23

07/23

CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

Recruiting

1000

Europe

Ribociclib

Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals

Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer

10/24

10/26

SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting

1332

Europe

Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy

GBG Forschungs GmbH, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER

HER2-negative Breast Cancer, Triple Negative Breast Cancer

03/27

03/29

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

neoMono, NCT04770272 / 2020-001651-40: Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy with Atezolizumab - CTX Therapy

Completed

416

Europe

Atezolizumab 840 MG in 14 ML Injection, Tecentriq, Atezolizumab 1200 MG in 20 ML Injection, Carboplatin, Paclitaxel, Epirubicin, Cyclophosphamide, Biopsy Arm A, Biopsy Arm B, Surgery

Palleos Healthcare GmbH, Roche Pharma AG, Phaon Scientific GmbH, University Hospital, Essen, University Hospital Erlangen

Triple-negative Breast Cancer

07/23

10/24

ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting

1/2

400

Europe, US, RoW

Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio

Stemline Therapeutics, Inc.

Breast Cancer, Metastatic Breast Cancer

12/26

12/28

NCT04101851: Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients with RCR and PCR in the Breast After NAST

Active, not recruiting

N/A

350

Europe

omission of SLNB

Breast Cancer Female, Breast Cancer

01/28

AXSANA, NCT04373655: AXillary Surgery After NeoAdjuvant Treatment

Recruiting

N/A

3000

Europe

Breast Cancer

04/30

PROOFS, NCT05792150: -Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS

Recruiting

N/A

1470

Europe

West German Study Group, Agendia

Female Breast Cancer

03/35

06/35



	Diseases Companies Products Productz Mechanisms of Action Sites